following a full submission:
roxadustat (Evrenzo®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
SMC restriction: for use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation.
Roxadustat was non-inferior to an erythropoiesis stimulating agent (ESA) and superior to placebo for improving haemoglobin (Hb) levels in adults with anaemia in CKD who were NDD.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- roxadustat (Evrenzo)
- SMC ID:
- SMC2461
- Indication:
For treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 August 2022